跳至主要内容
临床试验/NCT04571398
NCT04571398Unknown不适用

A Study of ApricityRx™ Digital Therapeutic for Management of Immune-Related Adverse Events in Patients on Immuno-Oncology Therapy

Apricity Health, Inc1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2019年11月19日最近更新:
适应症

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
Evaluate digital therapeutic mobile app to capture and transmit to care team patient-generated health data and access education content on IO and irAEs

研究概览

简要总结

Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed cancer diagnosis
  • Prescribed treatment with immune-checkpoint inhibitor
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent document.

排除标准

  • Uncomfortable with or unwilling to use digital or mobile technology
  • Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow
  • Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.

结局指标

主要结局

Evaluate digital therapeutic mobile app to capture and transmit to care team patient-generated health data and access education content on IO and irAEs

时间窗: 12 weeks

Number of times and percentage of study participants who use the app to report patient reported health data during a 12 week period and access education videos.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Study of ApricityRx™ for Management of IR-AEs in... | 临床试验